Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $137 from $122 and keeps an Outperform rating on the shares following last week’s approval of Symbravo for migraines. The firm says multiple near-term data-related catalysts could provide further stock upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $190 from $180 at Truist
- Axsome Therapeutics price target raised to $132 from $116 at Baird
- Axsome Therapeutics hosts SYMBRAVO FDA approval investor event
- Axsome Therapeutics price target raised to $190 from $180 at H.C. Wainwright
- Axsome Therapeutics announces FDA approval of Symbravo